INDV
Get informed when a big investor buys or sells
+ FollowOvervalued by 103.9% based on the discounted cash flow analysis.
| Market cap | $4.47 Billion |
|---|---|
| Enterprise Value | $4.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.68 |
| Beta | 1.11 |
| Outstanding Shares | 125,352,000 |
| P/E Ratio | 12.62 |
|---|---|
| PEG | 14.12 |
| Price to Sales | 3.25 |
| Price to Book Ratio | -16.23 |
| Enterprise Value to Revenue | 3.38 |
| Enterprise Value to EBIT | 12.86 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 2.98%▼ 94.85% |
|---|---|
| Total Invested | $133.88M▼ 97.34% |
| Investors Holding | 9▼ 339.00% |
No data
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...